Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency

Crescent Gbeto; Sylvie Quaranta; Roxane Mari; Raphaelle Fanciullino; Catherine Roche; Sophie Nahon; Caroline Solas; L’houcine Ouafik; Bruno Lacarelle; Thierry Allegre; Joseph Ciccolini

doi:10.2217/pgs-2019-0028

Journal articles

Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency

Crescent Gbeto ¹ Sylvie Quaranta ² Roxane Mari ¹ Raphaelle Fanciullino ³ Catherine Roche ² Sophie Nahon ² Caroline Solas ^{2, 3} L’houcine Ouafik ^{4, 5} Bruno Lacarelle ^{6, 3} Thierry Allegre ⁷ Joseph Ciccolini ^{3, 2}

1 CHIAP - Centre Hospitalier d'Aix en Provence [Aix-en-Provence]

2 Laboratoire de Biologie médicale, AP-HM

3 SMARTc - Simulation and Modeling of Adaptive Response for Therapeutics in Cancer

CRCM - Centre de Recherche en Cancérologie de Marseille

4 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]

5 INP - Institut de neurophysiopathologie

6 Pharmacocinétique Toxicocinétique - [Hôpital de la Timone - APHM]

7 Service Hématologie et Médecine Interne

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-02483216
Contributor : l'Houcine Ouafik <>
Submitted on : Tuesday, February 18, 2020 - 2:57:10 PM
Last modification on : Wednesday, August 19, 2020 - 12:08:26 PM

Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency

Identifiers

Collections

Citation

Export

Metrics

80

Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency

Identifiers

Collections

Citation

Export

Share

Metrics

80